Secor Capital Advisors’s Achillion Pharmaceuticals ACHN Stock Holding History

Secor Capital Advisors’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-23,014	Closed	-$65K	–	627
2018 Q2	$65K	Sell	23,014 -37,364	-62%	-$127K	0.01%	475
2018 Q1	$224K	Sell	60,378 -374	-0.6%	-$1.22K	0.02%	459
2017 Q4	$175K	Sell	60,752 -89,065	-59%	-$324K	0.01%	455
2017 Q3	$673K	Buy	149,817 +95,725	+177%	+$425K	0.06%	313
2017 Q2	$248K	Buy	+54,092	New	+$217K	0.02%	415
2017 Q1	–	Sell	-71,428	Closed	-$295K	–	650
2016 Q4	$295K	Sell	71,428 -151,405	-68%	-$805K	0.04%	408
2016 Q3	$1.8M	Buy	222,833 +135,663	+156%	+$1.15M	0.2%	160
2016 Q2	$680K	Buy	87,170 +63,579	+270%	+$545K	0.09%	317
2016 Q1	$182K	Buy	+23,591	New	+$173K	0.03%	558
2014 Q1	–	Sell	-61,651	Closed	-$205K	–	420
2013 Q4	$205K	Buy	+61,651	New	+$179K	0.08%	297

Other funds holding ACHN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Secor Capital Advisors's ACHN Position: Q3 2018 in Review

Secor Capital Advisors sold out of Achillion Pharmaceuticals (ACHN) in Q3 2018, closing a stake of 23,014 shares — an estimated $65K sold.

Secor Capital Advisors first reported a position in ACHN in Q4 2013 and held it in 10 quarters. The position peaked at $1.8M in Q3 2016. 137 funds tracked by Wall St. Rank hold ACHN as of Q3 2018.

Secor Capital Advisors reported no remaining Achillion Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Secor Capital Advisors sold 23,014 Achillion Pharmaceuticals shares in Q3 2018, an estimated $65K.
Secor Capital Advisors first reported a position in Achillion Pharmaceuticals in Q4 2013 and held it in 10 quarters.
Secor Capital Advisors's Achillion Pharmaceuticals position peaked at $1.8M in Q3 2016.
137 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2018.

Based on Secor Capital Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.